¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-13

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-13
±³À°ÀÏÀÚ : 2022-05-13
±³À°Àå¼Ò : °æÁÖ È­¹éÄÁº¥¼Ç¼¾ÅÍ  
±³À°ÁÖÁ¦ : Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : ÀÌ¿¬ÁÖ
¿¬¶ôó : 02-714-9071  
À̸ÞÀÏ : diabetes@kams.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 1300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 170,000¿ø      
ºñ°í È¸¿ø ÀÇ»ç: 120,000¿ø ºñȸ¿ø ÀÇ»ç: 170,000¿ø ȸ¿ø ºñÀÇ»ç: 70,000¿ø ºñȸ¿ø ºñÀÇ»ç: 120,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 08:30~08:50 Initial combination therapy for T2DM; for whom, what is the optimal combination?  ¹ÚÁ¤È¯(ÇѾçÀÇ´ë ³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:00~09:25 Effect of SGLT2 inhibitors in heart failure with preserved ejection fraction  ½ÉÁö¿µ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:25~09:50 Cardiovascular and renal outcomes with Finerenone with type 2 diabetes with CKD  È²Çö¼®(°æÈñÀÇ´ë ½ÅÀå³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:50~10:15 Post-hoc analysis of AMPLITUDE-O study (CVOT study of Efpeglenatide)  ¹é½ÂÀç(Çѹ̾àÇ° ½Å¾àÀӻ󰳹ߺ»ºÎ) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 10:15~10:40 Safety and efficacy of GLP-1/GIP dual agonists in patients with type 2 diabetes  Á¶¿µ¹Î(¼­¿ïÀÇ´ë ³»°ú) 
Åä·Ð 05-13 °æÁÖ HICO Room1 10:40~11:00 Panel discussion  Á¤Ã¢ÈñÀ̻󿭼­¹ÌÇýÀ±ÁöÈñ(¿ï»êÀÇ´ë ³»°ú°æÈñÀÇ´ë ³»°ú¼øõÇâÀÇ´ë ³»°úÀü³²ÀÇ´ë ³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 11:30~12:10 Tirzepatide: a dual GIP and GLP-1 receptor agonist in development for the treatment of type 2 diabetes, obesity and non-alcoholic steatohepatitis  Juan Pablo Frias(Velocity Clinical Research USA) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 12:10~13:20 Intermittently scanned CGM: clinical evidence and practical tips  Áø»ó¸¸(¼º±Õ°üÀÇ´ë ³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 14:50~15:30 Sirtuin 6 as a multitasking player in immune cell differentiation and metabolic diseases  ¹Úº´Çö(ÀüºÏÀÇ´ë »ýÈ­ÇкÐÀÚ»ý¹°Çб³½Ç) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 15:50~16:20 Self-care solutions for GDM patients  ¹ÚÇýÀº(°æÈñÀÇ·á¿ø °£È£°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 16:20~16:50 Self-care solutions for children and adolescents with diabetes  À̽ÂÈñ(°æºÏ´ëÇб³¾î¸°À̺´¿ø °£È£°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 16:50~17:20 Self-care solutions for young diabetic patients  ±è¼±¿µ(»ï¼º¼­¿ïº´¿ø °£È£°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 17:20~17:50 Self-care solutions for elderly diabetic patients  ¹Ú¼±¿µ(°è¸í´ëÇб³ µ¿»êÀÇ·á¿ø °£È£°ú) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-13""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³âµµ ÀÇ°ú´ëÇÐ ±³À°°úÁ¤ °³¹ß°ú Æò°¡ ¿öÅ©¼ó(2ÀÏÂ÷) : 2022-05-14
´ÙÀ½±Û 2022³âµµ ÀÇ°ú´ëÇÐ ±³À°°úÁ¤ °³¹ß°ú Æò°¡ ¿öÅ©¼ó(1ÀÏÂ÷) : 2022-05-13
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 36 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 33 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 35 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 42 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 36 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 26 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 8 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 10 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 24 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 13 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 11 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 28 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 15 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 25 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 18 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷